Compare MYGN & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYGN | GNE |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.1M | 408.2M |
| IPO Year | 1996 | 2011 |
| Metric | MYGN | GNE |
|---|---|---|
| Price | $5.78 | $16.57 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $4.11 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 54.3K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.78% |
| EPS Growth | N/A | ★ 95.65 |
| EPS | N/A | ★ 0.54 |
| Revenue | ★ $771,400,000.00 | $425,202,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.47 | $1.86 |
| P/E Ratio | ★ N/A | $31.07 |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $2.74 | $12.69 |
| 52 Week High | $8.50 | $17.11 |
| Indicator | MYGN | GNE |
|---|---|---|
| Relative Strength Index (RSI) | 73.82 | 56.80 |
| Support Level | $5.57 | $13.46 |
| Resistance Level | $6.34 | $17.11 |
| Average True Range (ATR) | 0.33 | 0.45 |
| MACD | 0.16 | -0.05 |
| Stochastic Oscillator | 90.50 | 64.44 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.